Celldex Therapeutics (CLDX) Short Interest Ratio & Short Volume → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free CLDX Stock Alerts $42.56 +1.70 (+4.16%) (As of 05/3/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Celldex Therapeutics Short Interest DataCurrent Short Volume6,750,000 sharesPrevious Short Volume6,560,000 sharesChange Vs. Previous Month+2.90%Dollar Volume Sold Short$263.72 millionShort Interest Ratio / Days to Cover7.3Last Record DateApril 15, 2024Outstanding Shares55,900,000 sharesPercentage of Shares Shorted12.08%Today's Trading Volume605,044 sharesAverage Trading Volume861,537 sharesToday's Volume Vs. Average70% Short Selling Celldex Therapeutics ? Sign up to receive the latest short interest report for Celldex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCLDX Short Interest Over TimeCLDX Days to Cover Over TimeCLDX Percentage of Float Shorted Over Time Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… Celldex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20246,750,000 shares $263.72 million +2.9%N/A7.3 $39.07 3/31/20246,560,000 shares $275.32 million +11.2%N/A6.9 $41.97 3/15/20245,900,000 shares $247.86 million -8.0%N/A6.4 $42.01 2/29/20246,410,000 shares $308.06 million -7.6%N/A7.4 $48.06 2/15/20246,940,000 shares $255.39 million +3.4%N/A9.3 $36.80 1/31/20246,710,000 shares $236.33 million +7.9%N/A8.5 $35.22 Get the Latest News and Ratings for CLDX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20246,220,000 shares $261.49 million -5.6%N/A7.6 $42.04 12/31/20236,590,000 shares $261.36 million -10.3%N/A8.6 $39.66 12/15/20237,350,000 shares $273.05 million -8.9%N/A9.6 $37.15 11/30/20238,070,000 shares $243.79 million +2.4%N/A11.1 $30.21 11/15/20237,880,000 shares $224.82 million +40.2%N/A11.3 $28.53 10/31/20235,620,000 shares $132.18 million +0.9%N/A9.2 $23.52 10/15/20235,570,000 shares $145.60 million -3.3%N/A12.1 $26.14 9/30/20235,760,000 shares $158.52 million -5.4%N/A13.1 $27.52 9/15/20236,090,000 shares $170.22 million -3.3%N/A14.3 $27.95 8/31/20236,300,000 shares $175.77 million -3.7%N/A13.5 $27.90 8/15/20236,540,000 shares $205.55 million +8.5%N/A14.3 $31.43 7/31/20236,030,000 shares $213.22 million -3.8%N/A13.8 $35.36 7/15/20236,270,000 shares $233.81 million +1.8%N/A13.5 $37.29 6/30/20236,160,000 shares $209.01 million +2.7%N/A11 $33.93 6/15/20236,000,000 shares $221.22 million +3.5%N/A9.8 $36.87 5/31/20235,800,000 shares $184.44 million +7.0%N/A9.3 $31.80 5/15/20235,420,000 shares $185.69 million +1.1%N/A8.4 $34.26 4/30/20235,360,000 shares $168.52 million +3.5%N/A8.4 $31.44 4/15/20235,180,000 shares $156.90 million -1.7%N/A8.6 $30.29 3/31/20235,270,000 shares $189.61 million +38.0%N/A9.9 $35.98 3/15/20233,820,000 shares $167.13 million +5.5%N/A8 $43.75 2/28/20233,620,000 shares $154.90 million +4.3%N/A7.5 $42.79 2/15/20233,470,000 shares $148.79 million +4.5%N/A7.7 $42.88 1/31/20233,320,000 shares $146.28 million -4.3%N/A6.8 $44.06 1/15/20233,470,000 shares $159.69 million +1.8%N/A7 $46.02 12/30/20223,410,000 shares $151.98 million -17.2%N/A6.8 $44.57 12/15/20224,120,000 shares $182.47 million +1.7%N/A8 $44.29 11/30/20224,050,000 shares $150.21 million -1.9%N/A9 $37.09 11/15/20224,130,000 shares $151.53 million -8.2%N/A9 $36.69 10/31/20224,500,000 shares $158.09 million -0.9%N/A9.7 $35.13 10/15/20224,540,000 shares $142.74 million -1.5%N/A9.3 $31.44 9/30/20224,610,000 shares $129.59 million +2.4%N/A9 $28.11 9/15/20224,500,000 shares $136.40 million +2.3%N/A6.2 $30.31 8/31/20224,400,000 shares $133.76 million +4.0%N/A5.6 $30.40Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. CLDX Short Interest - Frequently Asked Questions What is Celldex Therapeutics' current short interest? Short interest is the volume of Celldex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 6,750,000 shares of CLDX short. Learn More on Celldex Therapeutics' current short interest. What is a good short interest ratio for Celldex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLDX shares currently have a short interest ratio of 7.0. Learn More on Celldex Therapeutics's short interest ratio. Which institutional investors are shorting Celldex Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Celldex Therapeutics: Concourse Financial Group Securities Inc., and Goldman Sachs Group Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Celldex Therapeutics' short interest increasing or decreasing? Celldex Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 6,750,000 shares, an increase of 2.9% from the previous total of 6,560,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Celldex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies compare to Celldex Therapeutics: Myriad Genetics, Inc. (6.08%), Intellia Therapeutics, Inc. (15.13%), Riot Platforms, Inc. (11.94%), Neogen Co. (8.15%), QuidelOrtho Co. (4.05%), Aspira Women's Health Inc. (2.52%), Lantheus Holdings, Inc. (6.95%), CONMED Co. (12.63%), Deciphera Pharmaceuticals, Inc. (11.45%), TG Therapeutics, Inc. (25.55%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Celldex Therapeutics stock? Short selling CLDX is an investing strategy that aims to generate trading profit from Celldex Therapeutics as its price is falling. CLDX shares are trading up $1.34 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Celldex Therapeutics? A short squeeze for Celldex Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CLDX, which in turn drives the price of the stock up even further. How often is Celldex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLDX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: MYGN Short Interest Data NTLA Short Interest Data RIOT Short Interest Data NEOG Short Interest Data QDEL Short Interest Data AWH Short Interest Data LNTH Short Interest Data CNMD Short Interest Data DCPH Short Interest Data TGTX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CLDX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits